Date: 2016-10-26
Type of information: Nomination
Compound:
Company: Merus (The Netherlands)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On October 26, 2016, Merus announced the appointment of L. Andres Sirulnik to the position of Chief Medical Officer, where he will be responsible for leading the Company's global clinical development strategy and clinical operations. Dr. Sirulnik will report to Ton Logtenberg, Chief Executive Officer of Merus, and will be based in the Company’s US Cambridge office.
- Prior to joining Merus, Dr. Sirulnik held numerous positions of increasing responsibility at Novartis, most recently serving as Vice President and Senior Global Clinical Program Head where he oversaw the clinical strategy for the immune-oncology portfolio. Prior, Dr. Sirulnik served as attending physician at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital, and was a fellow in Hematology/Oncology at Mount Sinai Health System in New York City.
Financial terms:
Latest news:
Is general: Yes
